Pediatric hematology-oncology
Pediatric Research International GmbH is involved in clinical research focused on acute myeloid leukemia in children and adolescents, with attention to refractory and relapsed disease.
- Paediatric acute myeloid leukemia
- Relapsed and refractory leukemia
- Childhood cancer
The sponsor’s activity is centered on treatment strategies for high-risk pediatric leukemia across multiple collaborating sites in Europe and beyond.
Molecularly defined leukemia subtypes
Its research interests include KMT2A rearrangements, NUP98 rearrangements, and NPM1-mutated AML, reflecting a focus on genetically characterized disease subgroups.
- KMT2A-r AML
- NUP98-r AML
- NPM1-mut AML
This emphasis supports clinical investigation in biologically distinct leukemia populations with limited therapeutic options.
Combination antileukemic therapy
The sponsor funds research in combination treatment approaches for pediatric leukemia, including regimens pairing menin inhibition with established chemotherapy backbones.
- Revumenib-based therapy
- FLA chemotherapy
- Combination regimens
These studies are directed toward treatment-resistant disease where new therapeutic options are needed.
Pediatric response assessment
Clinical research activity also involves pediatric-specific evaluation of treatment activity in acute myeloid leukemia, using response categories tailored to younger patients.
- Overall response rate
- Pediatric response criteria
- Hematologic remission
These outcomes are relevant to assessing disease control in multicenter pediatric leukemia studies.
